Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 Jun; 84(11): 1488–1496.
PMCID: PMC2363667

Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negativeatients


Matrix metalloprotease-9 (MMP-9; 92 kDa type IV collaganase, gelatinase B) is regarded as, important for degradation of the basement membrane and extracellular matrix during cancer invasion and other tissue-remodelling events. In this study we evaluate the prognostic value of MMP-9, by immunoperoxidase staining in a series of 210 breast cancer tissues. The results were quantitated using the HSCORE system, which consider both staining intensity and the percentage of cells stained at given intensities. MMP-9 status was compared with the concentration of cytosolic Cathepsin-D and with other established prognostic factors, in terms of disease free survival and overall survival. The median follow-up period was 62 months. MMP-9 staining was observed primarily in cancer cells, and to a lesser degree in surrounding stromal cells. MMP-9 expression was not detected in normal breast tissue. Levels of MMP-9 expression below the cut-off point were more frequently observed in larger (P = 0.014), invasive ductal histologic (P = 0.037), progesterone receptor (PR)-negative and PR-strong positive tumours (P< 0.001), as well as samples belonging to patients with stage III-IV disease (P = 0.009) and age 45–55 years (P = 0.011). In univariate analysis, node-negative breast cancer patients with tumors positive for MMP-9 had a considerable reduction in risk for relapse (RR = 0.45;P = 0.039) or death (RR = 0.32;P = 0.009). Multivariate analysis indicated that MMP-9 status was an independent favourable predictor of OS (RR = 0.47;P = 0.034) in node-negative but not in node-positive patients. Our results suggest that MMP-9 may be an independent favourable prognostic factor in node-negative breast cancer patients. The overexpression of MMP-9 in breast cancer may be also used as a marker to subdivide node negative breast cancer patients in order to determine the optimal treatment modality. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: MMP-9, breast cancer, prognostic factor

Full Text

The Full Text of this article is available as a PDF (361K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ardavanis A, Scorilas A, Amanatidou A, Gerakini F, Missitzis I, Garoufali A, Pissakas G, Pateras C, Apostolikas N, Rigatos G, et al. Cathepsin D concentration in tumor cytosols improves the accuracy of prognostic evaluation of primary breast cancer. Anticancer Res. 1997 Mar-Apr;17(2B):1405–1409. [PubMed]
  • Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998 Aug;4(8):923–928. [PubMed]
  • Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat. 1998 Jul;50(2):97–116. [PubMed]
  • Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer. 1995 Mar 3;60(5):597–603. [PubMed]
  • Blavier L, DeClerck YA. Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development. Mol Biol Cell. 1997 Aug;8(8):1513–1527. [PMC free article] [PubMed]
  • Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbisa S, Liotta LA, Grigioni WF. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer. 1991 Jun 19;48(4):529–532. [PubMed]
  • Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989 Nov 1;64(9):1914–1921. [PubMed]
  • Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer. 1995 May;71(5):1025–1028. [PMC free article] [PubMed]
  • Elashry-Stowers D, Zava DT, Speers WC, Edwards DP. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies. Cancer Res. 1988 Nov 15;48(22):6462–6474. [PubMed]
  • Fridman R, Toth M, Peña D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995 Jun 15;55(12):2548–2555. [PubMed]
  • Garbett EA, Reed MW, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer. 1999 Sep;81(2):287–293. [PMC free article] [PubMed]
  • Hanemaaijer R, Sier CF, Visser H, Scholte L, van Lent N, Toet K, Hoekman K, Verheijen JH. MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate. Ann N Y Acad Sci. 1999 Jun 30;878:141–149. [PubMed]
  • Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996 Jul;149(1):273–282. [PMC free article] [PubMed]
  • Hewitt R, Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein. 1996;49(1-3):163–173. [PubMed]
  • Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990 Sep 21;62(6):1189–1204. [PubMed]
  • Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999 Oct;189(2):161–168. [PubMed]
  • Karameris A, Panagou P, Tsilalis T, Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med. 1997 Dec;156(6):1930–1936. [PubMed]
  • Kute TE, Huske MS, Shore A, Rhyne AL. Improvements in steroid receptor assays including rapid computer analysis of data. Anal Biochem. 1980 Apr;103(2):272–279. [PubMed]
  • Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000 Sep 1;56(3):527–532. [PubMed]
  • Mira E, Mañes S, Lacalle RA, Márquez G, Martínez-A C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology. 1999 Apr;140(4):1657–1664. [PubMed]
  • Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000 Mar;18(5):1135–1149. [PubMed]
  • Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Danø K. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer. 1996 Jan 3;65(1):57–62. [PubMed]
  • Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest. 1996 Jan;74(1):168–177. [PubMed]
  • Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Danø K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest. 1997 Oct;77(4):345–355. [PubMed]
  • Pacheco MM, Mourão M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis. 1998 Oct;16(7):577–585. [PubMed]
  • Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O. Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis. 1998 Apr;16(3):205–215. [PubMed]
  • Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer. 1998 Mar;77(6):926–931. [PMC free article] [PubMed]
  • Rha SY, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Chung HC. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat. 1997 Apr;43(2):175–181. [PubMed]
  • Rha SY, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Chung HC. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep. 1998 Jul-Aug;5(4):875–879. [PubMed]
  • Salamonsen LA, Butt AR, Hammond FR, Garcia S, Zhang J. Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab. 1997 May;82(5):1409–1415. [PubMed]
  • Scorilas A, Yotis J, Gouriotis D, Keramopoulos A, Ampela K, Trangas T, Talieri M. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res. 1993 Sep-Oct;13(5C):1895–1900. [PubMed]
  • Scorilas A, Yotis J, Stravolemos K, Gouriotis D, Keramopoulos A, Ampela K, Talieri M, Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res. 1995 Jul-Aug;15(4):1543–1547. [PubMed]
  • Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res. 1999 Apr;5(4):815–821. [PubMed]
  • Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer. 1999 Dec;81(8):1385–1391. [PMC free article] [PubMed]
  • Scorilas A, Diamandis EP, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, López-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clin Cancer Res. 1999 Jul;5(7):1778–1785. [PubMed]
  • Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM, Trangas T. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res. 2000 Oct 1;60(19):5427–5433. [PubMed]
  • Scorilas A, Black MH, Talieri M, Diamandis EP. Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun. 2000 Nov 19;278(2):349–359. [PubMed]
  • Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998 May 15;58(10):2209–2216. [PubMed]
  • Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res. 1997 Jan;88(1):72–81. [PubMed]
  • Thorpe SM, Christensen IJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer. 1993;29A(7):971–977. [PubMed]
  • Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993;24(3):209–218. [PubMed]
  • Visscher DW, Höyhtyä M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer. 1994 Nov 1;59(3):339–344. [PubMed]
  • Vizoso F, Sánchez LM, Díez-Itza I, Merino AM, López-Otín C. Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol. 1995 Jan;13(1):54–61. [PubMed]
  • Yan S, Sameni M, Sloane BF. Cathepsin B and human tumor progression. Biol Chem. 1998 Feb;379(2):113–123. [PubMed]
  • Yousef GM, Scorilas A, Diamandis EP. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics. 2000 Jan 1;63(1):88–96. [PubMed]
  • Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem. 2001 Jan 5;276(1):53–61. [PubMed]
  • Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res. 1998 Jun;4(6):1489–1497. [PubMed]
  • Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999 Jan 1;13(1):35–48. [PMC free article] [PubMed]
  • Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999 Jun 30;878:212–227. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...